Morgan Stanley Supernus Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 649,838 shares of SUPN stock, worth $21.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

649,838

Previous 677,667 4.11%

Holding current value

$21.6 Million

Previous $24.5 Million 13.15%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$31.17 - $40.0 $867,429 - $1.11 Million	-27,829 Reduced 4.11%	649,838 $21.3 Million
Q4 2024 Feb 14, 2025	SELL	$31.89 - $37.83 $1.54 Million - $1.83 Million	-48,446 Reduced 6.67%	677,667 $24.5 Million
Q3 2024 May 14, 2025	BUY	$25.77 - $35.16 $1.43 Million - $1.95 Million	55,546 Added 8.28%	726,113 $22.6 Million
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $1.43 Million - $1.95 Million	55,546 Added 8.28%	726,113 $22.6 Million
Q2 2024 May 14, 2025	SELL	$25.99 - $33.85 $184,529 - $240,335	-7,100 Reduced 1.05%	670,567 $17.9 Million
Q2 2024 Oct 17, 2024	BUY	$25.99 - $33.85 $528,662 - $688,542	20,341 Added 3.13%	670,567 $17.9 Million
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $528,662 - $688,542	20,341 Added 3.13%	670,567 $17.9 Million
Q1 2024 Oct 17, 2024	SELL	$27.11 - $35.17 $551,444 - $715,392	-20,341 Reduced 3.03%	650,226 $22.2 Million
Q1 2024 Aug 16, 2024	SELL	$27.11 - $35.17 $1.98 Million - $2.57 Million	-73,129 Reduced 10.11%	650,226 $22.2 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $1.98 Million - $2.57 Million	-73,129 Reduced 10.11%	650,226 $22.2 Million
Q4 2023 Aug 16, 2024	BUY	$22.72 - $29.68 $1.2 Million - $1.57 Million	52,788 Added 7.87%	723,355 $20.9 Million
Q4 2023 Feb 13, 2024	BUY	$22.72 - $29.68 $4.43 Million - $5.78 Million	194,776 Added 36.85%	723,355 $20.9 Million
Q3 2023 Nov 15, 2023	SELL	$27.57 - $32.91 $753,184 - $899,068	-27,319 Reduced 4.91%	528,579 $14.6 Million
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $449,038 - $581,453	15,013 Added 2.78%	555,898 $16.7 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $6.62 Million - $7.97 Million	-189,558 Reduced 25.95%	540,885 $19.6 Million
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $6.68 Million - $8.13 Million	214,709 Added 41.63%	730,443 $26.1 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $1.2 Million - $1.48 Million	41,705 Added 8.8%	515,734 $17.5 Million
Q2 2022 Oct 27, 2022	BUY	$25.33 - $34.25 $6.11 Million - $8.27 Million	241,325 Added 103.7%	474,029 $13.7 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $6.11 Million - $8.27 Million	241,325 Added 103.7%	474,029 $13.7 Million
Q1 2022 Oct 27, 2022	SELL	$28.51 - $32.9 $6.88 Million - $7.94 Million	-241,325 Reduced 50.91%	232,704 $7.52 Million
Q1 2022 May 13, 2022	SELL	$28.51 - $32.9 $1.29 Million - $1.49 Million	-45,348 Reduced 16.31%	232,704 $7.52 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $1.41 Million - $1.82 Million	53,295 Added 23.71%	278,052 $8.11 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $5.29 Million - $7.06 Million	224,757 New	224,757 $6 Million

Others Institutions Holding SUPN

# of Institutions

305

Shares Held

60.8M

Call Options Held

8.8K

Put Options Held

6.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.78B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account